logo

LH

Labcorp
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 2
consensus rating "Strong Buy"
Low Cash Short-term Debt Ratio
Revenue Beats Expectation
EPS Below Expectations

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About LH

Labcorp Holdings Inc.

A leading global life sciences company that provides clinical testing services for healthcare industry

Healthcare Providers and Services
Invalid Date
04/24/1991
New York Stock Exchange
70000
12-31
Common stock
358 South Main Street, Burlington, North Carolina, 27215
--
Labcorp Holdings Inc., a Delaware corporation, was founded in 1971. The Company is a leading global life sciences company that is deeply integrated in guiding patient care. The Company provides comprehensive clinical laboratory and end-to-end drug development services through its LabCorp Diagnostics (LCD) and Covance Drug Development (CDD) divisions. LabCorp is positioned at the fusion of research and care delivery for more precise and personalized healthcare, combining world-class diagnostic and drug development capabilities.

Company Financials

EPS

LH has released its 2024 Q4 earnings. EPS was reported at 3.45, versus the expected 3.39, beating expectations. The chart below visualizes how LH has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

LH has released its 2024 Q4 earnings report, with revenue of 3.33B, reflecting a YoY change of 9.76%, and net profit of 143.60M, showing a YoY change of 186.09%. The Sankey diagram below clearly presents LH’s revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime